A Study in Healthy Men to Test How Bosentan Influences the Amount of Zongertinib in the Blood

NCT07649941 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-07-27

No results posted yet for this study

Summary

The main objective of this trial is to investigate the effect of a moderate CYP 3A inducer bosentan on the pharmacokinetics of zongertinib.

Conditions

  • Healthy

Interventions

DRUG

Zongertinib

Zongertinib

DRUG

Bosentan

Bosentan

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2026-08-19
Completion
2026-08-19

Countries

  • Germany

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07649941 on ClinicalTrials.gov